Drug Trial Radar · NCT05410730
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
Last checked: Nov 19, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 23, 2022
Primary completion
May 2025
Study completion May 2027
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316. To evaluate the preliminary efficacy of SHR-1501 alone or in combination with BCG or SHR-1316 in the treatment of NMIBC.
Conditions
- High-risk NMIBC
Interventions
SHR-1501Drug
SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: 21 Days
- Maximum tolerated doseTime frame: Approximately 2years
- Recommended Phase 2 dose (RP2D)Time frame: Approximately 2 years.
- CR Rate (cohort 2)Time frame: Approximately 4 years.
- 12-month DFS Rate (cohort 1、3、4)Time frame: Approximately 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.